JP6374383B2 - Ｃｏｘ阻害薬を含有する経皮製剤 - Google Patents

Ｃｏｘ阻害薬を含有する経皮製剤 Download PDF

Info

Publication number
JP6374383B2
JP6374383B2 JP2015524850A JP2015524850A JP6374383B2 JP 6374383 B2 JP6374383 B2 JP 6374383B2 JP 2015524850 A JP2015524850 A JP 2015524850A JP 2015524850 A JP2015524850 A JP 2015524850A JP 6374383 B2 JP6374383 B2 JP 6374383B2
Authority
JP
Japan
Prior art keywords
gel
active ingredient
celecoxib
menthol
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015524850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523408A (ja
Inventor
ミクラージク エンドレ
ミクラージク エンドレ
スパイチ タマーシュ
スパイチ タマーシュ
サカーイネー シンカ アーゴタ
サカーイネー シンカ アーゴタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6374383(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Publication of JP2015523408A publication Critical patent/JP2015523408A/ja
Application granted granted Critical
Publication of JP6374383B2 publication Critical patent/JP6374383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015524850A 2012-07-31 2013-07-31 Ｃｏｘ阻害薬を含有する経皮製剤 Active JP6374383B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/562,686 2012-07-31
US13/562,686 US10045935B2 (en) 2012-07-31 2012-07-31 Transdermal formulation containing COX inhibitors
PCT/HU2013/000080 WO2014020366A1 (en) 2012-07-31 2013-07-31 Transdermal formulation containing cox inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018057364A Division JP7210833B2 (ja) 2012-07-31 2018-03-26 Ｃｏｘ阻害薬を含有する経皮製剤

Publications (2)

Publication Number Publication Date
JP2015523408A JP2015523408A (ja) 2015-08-13
JP6374383B2 true JP6374383B2 (ja) 2018-08-15

Family

ID=49231593

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015524850A Active JP6374383B2 (ja) 2012-07-31 2013-07-31 Ｃｏｘ阻害薬を含有する経皮製剤
JP2018057364A Active JP7210833B2 (ja) 2012-07-31 2018-03-26 Ｃｏｘ阻害薬を含有する経皮製剤
JP2021199410A Active JP7384885B2 (ja) 2012-07-31 2021-12-08 Ｃｏｘ阻害薬を含有する経皮製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018057364A Active JP7210833B2 (ja) 2012-07-31 2018-03-26 Ｃｏｘ阻害薬を含有する経皮製剤
JP2021199410A Active JP7384885B2 (ja) 2012-07-31 2021-12-08 Ｃｏｘ阻害薬を含有する経皮製剤

Country Status (39)

Country Link
US (2) US10045935B2 (instruction)
EP (1) EP2879664B1 (instruction)
JP (3) JP6374383B2 (instruction)
KR (1) KR20150032892A (instruction)
CN (1) CN104768530B (instruction)
AU (2) AU2013298294A1 (instruction)
BR (1) BR112015002041B1 (instruction)
CA (1) CA2880442C (instruction)
CL (1) CL2015000240A1 (instruction)
CO (1) CO7240432A2 (instruction)
CR (1) CR20150044A (instruction)
CU (1) CU24246B1 (instruction)
CY (1) CY1123805T1 (instruction)
DK (1) DK2879664T3 (instruction)
EA (1) EA033950B1 (instruction)
EC (1) ECSP15003613A (instruction)
ES (1) ES2841992T3 (instruction)
GE (1) GEP20176630B (instruction)
HR (1) HRP20210008T1 (instruction)
HU (1) HUE053418T2 (instruction)
IL (1) IL236988B (instruction)
IN (1) IN2015DN01329A (instruction)
LT (1) LT2879664T (instruction)
MA (1) MA37880B1 (instruction)
MD (1) MD20150018A2 (instruction)
MX (1) MX361697B (instruction)
NI (1) NI201500007A (instruction)
NZ (1) NZ704567A (instruction)
PE (1) PE20150755A1 (instruction)
PH (1) PH12015500200A1 (instruction)
PL (1) PL2879664T3 (instruction)
PT (1) PT2879664T (instruction)
RS (1) RS61326B1 (instruction)
SG (1) SG11201500734SA (instruction)
SI (1) SI2879664T1 (instruction)
TN (1) TN2015000037A1 (instruction)
UA (1) UA116636C2 (instruction)
WO (1) WO2014020366A1 (instruction)
ZA (1) ZA201500744B (instruction)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018100299A (ja) * 2012-07-31 2018-06-28 エギシュ ヂョヂセルヂャール ザートケルエン ミケデ レースヴェーニタールササーグ Ｃｏｘ阻害薬を含有する経皮製剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CN108904812A (zh) * 2018-08-27 2018-11-30 邛崃市医疗中心医院 以卡波姆协同透皮剂的高透皮性防治肩周炎的外用药物
EP4087559A4 (en) * 2020-01-10 2024-04-17 Briori Biotech, LLC TOPICAL COMPOSITIONS CONTAINING ROFECOXIB, AND METHODS OF MANUFACTURE AND METHODS OF USE THEREOF
CN114601789B (zh) * 2022-03-29 2024-03-26 辽宁方诺生物科技有限公司 一种塞来昔布凝胶剂及其制备方法和应用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998973A (en) 1975-04-07 1976-12-21 R. T. Vanderbilt Company, Inc. Thickening composition
FR2339392A1 (fr) 1976-02-02 1977-08-26 Oreal Compositions contenant des derives du silicium
GB2050160A (en) 1979-04-10 1981-01-07 Nottage H C Cosmetic protective cream
FR2471778A1 (fr) 1979-12-21 1981-06-26 Oreal Procede de traitement des cheveux en vue d'ameliorer leur aspect a l'aide d'une composition contenant un hydrolysat de lactalbumine
WO1984001710A1 (en) 1982-11-04 1984-05-10 Redken Laboratories Inc Cosmetic preparation
GB8320366D0 (en) 1983-07-28 1983-09-01 Gillette Co Hair relaxing compositions
GB8421112D0 (en) 1984-08-20 1984-09-26 Unilever Plc Pyroglutamic acid esters
GB8600568D0 (en) 1986-01-10 1986-02-19 Gillette Co Hair relaxing compositions
US4831023A (en) 1986-06-27 1989-05-16 Thames Pharmacal Co., Inc. Water washable vehicles for topical use
US4837019A (en) 1986-08-11 1989-06-06 Charles Of The Ritz Group Ltd. Skin treatment composition and method for treating burned skin
DE3805744C2 (de) 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US4720353A (en) 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
DE3714140A1 (de) 1987-04-28 1988-11-10 Lohmann Therapie Syst Lts Wirkstoffhaltiges pflaster zur kontrollierten verabreichung von wirkstoffen an die haut, seine verwendung sowie verfahren zur gesteuerten verabreichung von wirkstoffen an die haut
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JPH02145512A (ja) 1988-11-26 1990-06-05 Shin Etsu Chem Co Ltd 被膜形成型外用剤
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
DE4131678A1 (de) 1991-04-13 1992-10-15 Beiersdorf Ag Stabile multiple emulsionen
WO1993000873A1 (en) 1991-07-03 1993-01-21 Sano Corporation Composition and method for transdermal delivery of diclofenac
US5300286A (en) 1992-07-14 1994-04-05 Dow Corning Corporation Silicone emulsion for personal care application
US5210103A (en) 1992-09-02 1993-05-11 Basf Corporation Volatile silicone oil-blown integral skin foam
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9315755D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized formulation
FR2709131B1 (fr) 1993-08-18 1995-11-10 Cilag Laboratoire Dispositif de distribution d'une substance thérapeutique ou cosmétique dont le véhicule inerte est un polydiorganosiloxane volatil, et composition destinée à être utilisée dans le dispositif.
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5620692A (en) 1993-12-23 1997-04-15 Nurture, Inc. Oat oil compositions with useful cosmetic and dermatological properties
GB9404248D0 (en) 1994-03-05 1994-04-20 Boots Co Plc Pharmaceutical formulations
US5451405A (en) 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
IL116539A (en) 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
FR2738565B1 (fr) 1995-09-13 1997-11-28 Dior Christian Parfums Produits extraits d'une plante du genre commiphora, en particulier de la plante commiphora mukul, et extraits en contenant et leurs applications notamment en cosmetique
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
WO1997044008A1 (en) 1996-05-21 1997-11-27 Derma Sciences, Inc. Topical barrier composition containing silicone and bentonite
GB9611167D0 (en) 1996-05-29 1996-07-31 Glaxo Group Ltd Medicaments
DE69707887T2 (de) 1996-06-28 2002-04-11 Unilever Nv Antitranspirant/deodorant flüssige zusammensetzung
FR2751874B1 (fr) 1996-08-02 1998-08-28 Sederma Sa Nouvelles compositions cosmetiques pour embellir et eclaircir la peau
GB9618974D0 (en) 1996-09-11 1996-10-23 Glaxo Group Ltd Medicaments
US5747051A (en) 1996-09-27 1998-05-05 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid
US5756109A (en) 1996-09-27 1998-05-26 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing geranyl geraniol and retinol or retinyl esters
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6019997A (en) 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19700913C2 (de) 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
FR2763842B1 (fr) 1997-05-27 2000-09-15 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques contenant des derives de threonine ou de serine
FR2768335B1 (fr) 1997-09-12 2000-03-03 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant une association d'extrait d'algue et d'exopolysaccharide
IL122084A (en) 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
DE19750029A1 (de) 1997-11-12 1999-05-20 Merck Patent Gmbh Stabile kosmetische Formulierung enthaltend Butylmethoxydibenzoylmethan
DE19750030A1 (de) 1997-11-12 1999-05-20 Merck Patent Gmbh Lichtstabile kosmetische Formulierung enthaltend Butylmethoxydibenzoylmethan
US6187300B1 (en) 1997-12-17 2001-02-13 The Procter & Gamble Company Antiperspirant cream compositions having improved wash-off and antiperspirant efficacy
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US20060015058A1 (en) 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
MXPA01000973A (es) 1998-08-03 2002-06-04 Epigenesis Pharmaceuticals Inc Un nuevo agente analgesico antiinflamatorio y de cicatrizacion de heridas.
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
GB9828379D0 (en) 1998-12-22 1999-02-17 Unilever Plc Skin care composition
US6007829A (en) 1998-12-17 1999-12-28 Cheesebrough-Pond's Usa Co. Cosmetic skin care compositions containing succinate compounds
FR2791887B1 (fr) 1999-04-06 2004-04-23 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques renfermant des extraits vegetaux de pinus lambertania contre la secheresse cutanee de toute origine
PT2915534T (pt) 1999-04-23 2018-06-20 Leo Pharma As Composição farmacêutica para aplicação dérmica para uso no tratamento da psoríase compreendendo vitamina d e um corticosteroide
KR100319473B1 (ko) 1999-08-24 2002-01-05 김강권 실크아미노산 수용액을 주재로한 아이스크림류의 제조방법
US10179159B2 (en) 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
FR2802097B1 (fr) 1999-12-14 2002-12-13 Invest S Therapeutiques Essais Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
US20050074487A1 (en) 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
DE10004790B4 (de) 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
US6361806B1 (en) 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue
WO2001070210A2 (en) 2000-03-17 2001-09-27 Avocet Polymer Technologies, Inc. Methods for improving size and appearance of a wound
US6800297B2 (en) 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
US6589557B2 (en) 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
DE10032132A1 (de) 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
IN191090B (instruction) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
DE10042411A1 (de) 2000-08-30 2002-03-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Exemestan
GB0027769D0 (en) 2000-11-14 2000-12-27 Unilever Plc Cosmetic method of treating skin
GB0028355D0 (en) 2000-11-21 2001-01-03 Unilever Plc Cosmetic method of treating skin
GB0028706D0 (en) 2000-11-24 2001-01-10 Unilever Plc Cosmetic composition
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
OA12613A (en) 2001-05-31 2006-06-09 Pharmacia Corp Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol.
GB0119583D0 (en) 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
EP1448209A2 (en) 2001-10-23 2004-08-25 Ranbaxy Laboratories, Ltd. A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
US20030104019A1 (en) 2001-11-01 2003-06-05 Mcculloch Laura Composition for reducing enzymatic irritation to skin
DE10164531A1 (de) 2001-12-31 2003-07-17 Pharmatech Gmbh Zubereitung zur Oberflächenanästhesie der Haut
US6838078B2 (en) 2002-01-16 2005-01-04 3M Innovative Properties Company Film-forming compositions and methods
US20030180281A1 (en) 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
CA2479665C (en) 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20030199584A1 (en) 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US20030199537A1 (en) 2002-04-18 2003-10-23 Cannon John B. Polymorph of a pharmaceutical
JP2004075592A (ja) 2002-08-14 2004-03-11 Masahiko Abe 非イオン性ベシクルおよびその利用
CH696420A5 (de) 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
US20060241175A1 (en) 2002-09-27 2006-10-26 Joseph Schwarz Vehicle for topical delivery of anti-inflammatory compounds
US7138394B2 (en) 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
CN1777653A (zh) 2003-04-18 2006-05-24 默克专利股份有限公司 抗微生物颜料
ITRM20030204A1 (it) 2003-04-29 2004-10-30 Provincia Italiana Della Congregazi One Dei Figli Formulazione dermatologica.
FR2854897B1 (fr) 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
JPWO2004112837A1 (ja) 2003-05-23 2006-07-20 久光製薬株式会社 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン−１α生成抑制剤
WO2005000248A2 (en) 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
WO2005007129A2 (en) 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
WO2005011567A2 (en) 2003-08-04 2005-02-10 Foamix Ltd. Foam carrier containing amphiphilic copolymeric gelling agent
EP1656097A1 (en) 2003-08-07 2006-05-17 The Procter & Gamble Company Oil emulsions
WO2005044227A1 (en) 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
WO2005046600A2 (en) 2003-11-07 2005-05-26 Nexmed Holdings, Inc. Transdermal tulobuterol delivery
FR2862871B1 (fr) 2003-12-01 2008-05-30 Camet Anne Dupouy Composition cosmetique anti-pollution
US20050255133A1 (en) 2004-05-11 2005-11-17 Alpharx Inc. Topical composition for acne treatment
US20050255131A1 (en) 2004-05-11 2005-11-17 Mohan Vishnupad Clindamycin compositions and delivery system therefor
US7662855B2 (en) 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
US20070264319A1 (en) 2004-09-01 2007-11-15 Lebo David B Transdermal Antiemesis Delivery System, Method and Composition Therefor
US20070267035A1 (en) 2004-09-07 2007-11-22 Henkel Kommanditgesellschaft Auf Aktien Composition and Method for the Smoothing of Fibres Containing Keratin
US8653055B2 (en) 2004-09-15 2014-02-18 Teva Animal Health, Inc. Corticosteroid having low systemic absorption
WO2006041908A2 (en) 2004-10-08 2006-04-20 Noven Pharmaceuticals, Inc. Transdermal delivery of estradiol
WO2006091297A2 (en) 2005-02-23 2006-08-31 The Regents Of The University Of California Molecules to enhance percutaneous delivery and methods for discovery therefor
WO2006138035A1 (en) 2005-06-13 2006-12-28 Dow Corning Corporation Vehicle for the delivery of topical lipid soluble pharmaceutical agents
CA2618993A1 (en) 2005-08-13 2007-02-22 Collegium Pharmaceutical, Inc. Topical delivery with a carrier fluid
WO2007051596A1 (en) 2005-11-03 2007-05-10 Dsm Ip Assets B.V. Novel retinyl biotinates and use thereof
KR100658436B1 (ko) 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
AU2006326870A1 (en) 2005-12-22 2007-06-28 Apollo Life Sciences Transdermal delivery of pharmaceutical agents
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
HUP0900072A2 (hu) 2009-02-06 2010-09-28 Egis Gyogyszergyar Nyilvanosan Transzdermális gyógyszerkészítmények
EP2178519B1 (en) 2007-07-13 2012-04-25 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
WO2009031318A1 (ja) 2007-09-05 2009-03-12 Kowa Co., Ltd. 鎮痛・抗炎症剤含有外用剤
EP2222282A1 (en) 2007-11-15 2010-09-01 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief
US20100105750A1 (en) 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
KR20110127678A (ko) 2009-03-11 2011-11-25 코와 가부시키가이샤 진통·항염증제 함유 외용제
KR20110127687A (ko) 2009-03-11 2011-11-25 코와 가부시키가이샤 진통·항염증제 함유 외용제
WO2011149645A1 (en) * 2010-05-28 2011-12-01 Nuvo Research Inc. Topical etoricoxib formulation
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018100299A (ja) * 2012-07-31 2018-06-28 エギシュ ヂョヂセルヂャール ザートケルエン ミケデ レースヴェーニタールササーグ Ｃｏｘ阻害薬を含有する経皮製剤
JP2022022374A (ja) * 2012-07-31 2022-02-03 エギシュ ヂョヂセルヂャール ザートケルエン ミケデ レースヴェーニタールササーグ Ｃｏｘ阻害薬を含有する経皮製剤
JP7210833B2 (ja) 2012-07-31 2023-01-24 エギシュ ヂョヂセルヂャール ザートケルエン ミケデ レースヴェーニタールササーグ Ｃｏｘ阻害薬を含有する経皮製剤
JP7384885B2 (ja) 2012-07-31 2023-11-21 エギシュ ヂョヂセルヂャール ザートケルエン ミケデ レースヴェーニタールササーグ Ｃｏｘ阻害薬を含有する経皮製剤

Also Published As

Publication number Publication date
JP2022022374A (ja) 2022-02-03
IL236988A0 (en) 2015-03-31
HUE053418T2 (hu) 2021-07-28
NZ704567A (en) 2018-02-23
CU24246B1 (es) 2017-02-02
CY1123805T1 (el) 2022-05-27
CO7240432A2 (es) 2015-04-17
US10045935B2 (en) 2018-08-14
NI201500007A (es) 2015-06-10
PH12015500200A1 (en) 2015-03-16
JP2015523408A (ja) 2015-08-13
BR112015002041A2 (pt) 2017-07-04
CA2880442C (en) 2020-10-27
EA033950B1 (ru) 2019-12-12
JP7210833B2 (ja) 2023-01-24
EP2879664B1 (en) 2020-10-07
PL2879664T3 (pl) 2021-06-28
EA201590269A1 (ru) 2015-05-29
AU2013298294A1 (en) 2015-02-26
AU2018202875A1 (en) 2018-05-17
CN104768530B (zh) 2018-08-21
IL236988B (en) 2019-06-30
WO2014020366A1 (en) 2014-02-06
TN2015000037A1 (en) 2016-06-29
US20140037738A1 (en) 2014-02-06
DK2879664T3 (da) 2021-01-11
MA37880A1 (fr) 2016-02-29
HRP20210008T1 (hr) 2021-03-05
IN2015DN01329A (instruction) 2015-07-03
UA116636C2 (uk) 2018-04-25
LT2879664T (lt) 2021-01-25
BR112015002041B1 (pt) 2022-11-16
MD20150018A2 (ro) 2015-07-31
HK1211490A1 (en) 2016-05-27
CA2880442A1 (en) 2014-02-06
PE20150755A1 (es) 2015-06-07
MX361697B (es) 2018-12-14
ZA201500744B (en) 2016-10-26
SI2879664T1 (sl) 2021-02-26
CU20150010A7 (es) 2015-08-27
RS61326B1 (sr) 2021-02-26
CN104768530A (zh) 2015-07-08
MA37880B1 (fr) 2016-09-30
EP2879664A1 (en) 2015-06-10
JP2018100299A (ja) 2018-06-28
AU2018202875B2 (en) 2019-12-12
PT2879664T (pt) 2021-01-13
MX2015001387A (es) 2015-09-16
CR20150044A (es) 2015-07-01
ES2841992T3 (es) 2021-07-12
KR20150032892A (ko) 2015-03-30
SG11201500734SA (en) 2015-02-27
US20150231247A1 (en) 2015-08-20
ECSP15003613A (es) 2015-12-31
CL2015000240A1 (es) 2015-09-11
JP7384885B2 (ja) 2023-11-21
GEP20176630B (en) 2017-02-27

Similar Documents

Publication Publication Date Title
JP7384885B2 (ja) Ｃｏｘ阻害薬を含有する経皮製剤
US11154535B2 (en) Transdermal formulation containing COX inhibitors
JP6921493B2 (ja) 水中油型乳化組成物
JP2022501314A (ja) 局所用組成物
JP4195178B2 (ja) 消炎鎮痛外用剤
CN102458382B (zh) 莫米松和丙二醇的水包油乳状液
US10045965B2 (en) Transdermal formulation containing COX inhibitors
JP6517657B2 (ja) 外用組成物
OA17629A (en) Transdermal formulation containing COX inhibitors.
JP2004131472A (ja) 痔疾治療用軟膏
HK1211490B (zh) 包含cox抑制剂的透皮制剂
JP5662495B2 (ja) 可溶化剤形の医薬組成物
JP2023140460A (ja) 抗炎症成分を配合した乳化組成物
JP6110839B2 (ja) 可溶化剤形の医薬組成物
TW202011962A (zh) 醫藥組成物與抑制其形成結晶的方法
WO2022131083A1 (ja) 外用医薬組成物
HK40032644A (en) Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof
WO2008038806A1 (en) Antipruritic agent

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180619

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180719

R150 Certificate of patent or registration of utility model

Ref document number: 6374383

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250